CFTR and cystic fibrosis: It has now become the forefront of current pharmacological treatment for CF patients who have at least one F508del variant in the CFTR gene and it has been extended to several other misfolded variants (to date, Trikafta has been approved for 178 mutations, see https://www.trikafta.com/sites/default/files/patient-brochure.pdf) and the possibility of expanding its use is still under investigation [21, 22].